ArticleFrontiers in endocrinology2025
Systemic immune inflammatory index and mortality in chronic kidney disease.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evidence of immune-metabolic imbalance prior to sepsis: a prospective study in the UK Biobank.Frontiers in nutrition · 2026Article
- Research on the role and mechanisms of Cystatin 6 in disease pathosis and development.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) is common and linked to higher mortality rates, but its relationship with the systemic immunoinflammatory index (SII) remains unclear, highlighting the need for further research. Methods: The SII is calculated by multiplying the counts of platelets and neutrophils, followed by dividing that product by the lymphocyte count. A diagnosis of CKD is made when the estimated glomerular filtration rate (eGFR) is below 60 mL/min/1.73 m². To further analyze the data, a multivariable Cox regression analysis, along with subgroup assessments, was performed. Analysis of survival data and threshold effects suggests that SII is a crucial independent factor related to mortality from all causes and cardiovascular issues in individuals with chronic kidney disease. Results: The study comprised a total of 46,620 individuals, with a weighted average age (standard error) of 47.00 (0.18) years. Among individuals over 20 years old suffering from CKD, the log-transformed SII demonstrated a nonlinear relationship, revealing a U-shaped correlation with the mortality rates associated with all causes as well as cardiovascular diseases (CVD). When SII.log as the log values rise, the likelihood of dying from all causes and cardiovascular issues initially shows a decline. Nevertheless, this pattern shifts, leading to an increased risk of mortality once a certain limit is surpassed. The evaluation of threshold impacts identified important levels starting at 6.06 and 6.25, which corresponded to the lowest observed mortality risk when evaluated through the SII.log values. The likelihood of mortality from all causes escalated once these limits were surpassed (HR 0.75, 95% CI 0.64-0.88; HR 1.74, 95% CI 1.55-1.95). The likelihood of mortality due to CVD also elevated (HR 1.01, 95% CI 0.78-1.31; HR 1.91, 95% CI 1.50-2.44). Higher SII levels correlated with decreased survival and longevity. In CKD patients over 45 years, SII reliably predicted all-cause mortality (statistically significant) and was linked to cardiovascular and cancer deaths (not statistically significant). Conclusions: SII is an easily obtainable marker that may predict mortality in CKD patients over 45. More longitudinal research is needed to confirm its link with mortality rates (all causes, cardiovascular, and cancer) due to current limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.